OJAppS  Vol.5 No.9 , September 2015
Fuzzy Logic Strategy for Solving an Optimal Control Problem of Therapeutic Hepatitis C Virus Dynamics
Abstract: This paper aims at the development of an approach integrating the fuzzy logic strategy for a therapeutic hepatitis C virus dynamics optimal control problem. To test the efficiency of this strategy, the authors propose a numerical comparison with the direct method by taking the values of determinant parameters of this disease for people administrating the drugs. The results are in good agreement with experimental data.
Cite this paper: Ntaganda, J. , Haggar, M. and Mampassi, B. (2015) Fuzzy Logic Strategy for Solving an Optimal Control Problem of Therapeutic Hepatitis C Virus Dynamics. Open Journal of Applied Sciences, 5, 527-541. doi: 10.4236/ojapps.2015.59051.

[1]   Choo, Q.L., Kuo, G., Weiner, A.J., et al. (1989) Isolation of a cDNA Clone Derived from a Blood-Borne Non-A, Non-B Viral Hepatitis Genome. Science, 244, 359-362.

[2]   Simmonds, P., Bukh, J., Combet, C., et al. (2005) Consensus Proposals for a Unified System of Nomenclature of Hepatitis C Virus Genotypes. Hepatology, 42, 962-973.

[3]   Kim, W.R. (2002) The Burden of Hepatitis C in the United States. Hepatology, 36, S30-S34.

[4]   Alter, M.J. (2007) Epidemiology of Hepatitis C Virus Infection. World Journal of Gastroenterology, 13, 2436-2441.

[5]   Houghton, M. and Abrignani, S. (2005) Prospects for a Vaccine against the Hepatitis C Virus. Nature, 436, 961-966.

[6]   Shiratori, Y., Ito, Y., Yokosuka, O., Imazeki, F., Nakata, R., Tanaka, N., Arakawa, Y., Hashimoto, E., Hirota, K., Yoshida, H., Ohashi, Y. and Omata, M., Tokyo-Chiba Hepatitis Research Group (2005) Antiviral Therapy for Cirrhotic Hepatitis C: Association with Reduced Hepatocellular Carcinoma Development and Improved Survival. Annals of Internal Medicine, 142, 105-114.

[7]   Takaoka, A. and Yanai, H. (2006) Interferon Signalling Network in Innate Defence. Cellular Microbiology, 8, 907-922.

[8]   Li, K., Foy, E., Ferreon, J.C., Nakamura, M., Ferreon, A.C., Ikeda, M., et al. (2005) Immune Evasion by Hepatitis C Virus NS3/4A Protease-Mediated Cleavage of the Toll-Like Receptor 3 Adaptor Protein TRIF. Proceedings of the National Academy of Sciences of the United States of America, 102, 2992-2997.

[9]   Honda, K., Takaoka, A. and Taniguchi, T. (2006) Type I Interferon [Corrected] Gene Induction by the Interferon Regulatory Factor Family of Transcription Factors. Immunity, 25, 349-360.

[10]   Lee, S.H., Miyagi, T. and Biron, C.A. (2007) Keeping NK Cells in Highly Regulated Antiviral Warfare. Trends in Immunology, 28, 252-259.

[11]   Young, H.A. and Ortaldo, J. (2006) Cytokines as Critical Co-Stimulatory Molecules in Modulating the Immune Response of Natural Killer Cells. Cell Research, 16, 20-24.

[12]   Gil, M.P., Salomon, R., Louten, J. and Biron, C.A. (2006) Modulation of STAT1 Protein Levels: A Mechanism Shaping CD8 T-Cell Responses in Vivo. Blood, 107, 987-993.

[13]   Chen, J., Florian, J., Carter, W., Fleischer, R.D., Hammerstrom, T.S., Jadhav, P.R., Zeng, W., Murray, J. and Birnkrant, D. (2013) Earlier Sustained Virologic Response End Points for Regulatory Approval and Dose Selection of Hepatitis C Therapies. Gastroenterology, 144, 1450-1455.

[14]   Manns, M.P., Foster, G.R., Rockstroh, J.K., Zeuzem, S., Zoulim, F. and Houghton, M. (2007) The Way forward in HCV Treatment—Finding the Right Path. Nature Reviews Drug Discovery, 6, 991-1000.

[15]   Neumann, A.U., Lam, N.P., Dahari, H., Gretch, D.R., Wiley, T.E., Layden, T.J. and Perelson, A.S. (1998) Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon-α Therapy. Science, 282, 103-107.

[16]   Dixit, N.M., Layden-Almer, J.E., Layden, T.J. and Perelson, A.S. (2004) Modelling How Ribavirin Improves Interferon Response Rates in Hepatitis C Virus Infection. Nature, 432, 922-924.

[17]   Dahari, H., Lo, A., Ribeiro, R.M. and Perelson, A.S. (2007) Modeling Hepatitis C Virus Dynamics: Liver Regeneration and Critical Drug Efficacy. Journal of Theoretical Biology, 247, 371-381.

[18]   Lenhart, S. and Workman, J.T. (2007) Optimal Control Applied to Biological Methods.

[19]   Chakrabarty, S.P. and Joshi, H.R. (2009) Optimally Controlled Treatment Strategy Using Interferon and Ribavirin for Hepatitis C. Journal of Biological Systems, 17, 97-110.

[20]   Chakrabarty, S.P. (2009) Optimal Efficacy of Ribavirin in the Treatment of Hepatitis C. Optimal Control Applications and Methods, 30, 594-600.

[21]   Martin, N.K., Ashley, B., Pitcher, A.B., Vickerman, P., Vassal, A. and Hickman, M. (2011) Optimal Control of Hepatitis C Antiviral Treatment Programme Delivery for Prevention amongst a Population of Injecting Drug Users. PLoS ONE, 6, e22309.

[22]   Ntaganda, J.M. (2015) Modelling a Therapeutic Hepatitis C Virus Dynamics. International Journal of Scientific and Innovative Mathematical Research (IJSIMR), 3, 1-10. (Online)

[23]   Yakowitz, S.J. (1986) The Stagewise Kuhn-Tucker Condition and Differential Dynamic Programming. IEEE Transactions on Automatic Control, 31, 25-30.

[24]   Masmoudi, N.K. and Derbel, N. (2003) Optimal Control of Nonlinear Systems by Fuzzy Logic. ISCIII, Nabeul.

[25]   Sugeno, M. and Murakami, K. (1984) Fuzzy Parking Control of Model Car. 23rd IEEE Conference on Decision and Control, Las Vegas, 12-14 December 1984, 902-903.

[26]   Takagi, T. and Sugeno, M. (1985) Fuzzy Identification of Systems and Its Applications to Modeling and Control. IEEE Transactions on Systems, Man and Cybernetics, 15, 116-132.

[27]   Park, M.I., Kim, E., Ji, S. and Park, M. (1987) A New Approach to Fuzzy Modeling. IEEE Transactions on Fuzzy Systems, 5, 328-337.

[28]   Jacobson, D., Lele, D. and Speyer, J.L. (1971) New Necessary Conditions of Optimality for Control Problems with State-Variable Inequality Constraints. Journal of Mathematical Analysis and Applications, 35, 255-284.

[29]   Kwakernaak, H. and Savan, R. (1972) Linear Optimal Control Systems. Wiley Inter-Science, New York.

[30]   Trélat, E. (2005) Contrôle optimal: Théeorie et applications. Vuibert, Collection Mathématiques Concrètes.